[ad_1]
In recent years, doctors have become increasingly fearful, as drug-resistant bacteria continue to proliferate and the drugs used to treat their infections become less and less effective, but a new study in Australia is encouraging us 39; optimism.
Clostridium difficile infections: Race against resistance
A scientist from Flinders University has developed a new antibiotic that has proven very effective in treating Clostridium difficile infections (CDI), a bacterial infection that affects the large intestine. ICD is potentially life-threatening and is mainly concerned with people who need to take antibiotics for a long time, especially in the elderly.
Dr. Ramiz Boulos, badociate researcher at Flinders University and CEO of Boulos & Cooper Pharmaceuticals, points to the risk of CDI as a drug-resistant bacterium: "CDI cases are increasing and strains are becoming more deadly. If there is an imbalance in your intestines, it can begin to develop and release toxins that attack the lining of the intestine, resulting in symptoms, "he said.
Even worse, new strains of It's hard have arisen over the last decade and have led to several serious and serious epidemics around the world. Hospitals are particularly vulnerable to a particular strain, easily transmitted from one person to another, which has affected many American and European hospitals in recent years.
"It's disturbing when we consider that ICD is one of the most common infections contracted during hospital visits in the Western Hemisphere," says Boulos, " and the most likely cause of diarrhea in patients and hospital staff. "
Ramizol: the new weapon against drug-resistant bacteria?
New study by Boulos & Cooper, as well as Product Safety Labs, ToxStrategies and Flinders University, published in the newspaper Scientific reports offers a bit of hope in the fight against CDI.
In a recent study, a lethal dose of It's hard was administered to hamsters who were then given Ramizol to fight the infection. Positively, a significant number of hamsters were able to defend themselves from CDI and survived.
In addition, a safety study was conducted in rats and gave positive results. In total, 48 the rats received large doses of Ramizol on a 14 day period and this repeated exposure to the drug caused no serious side effects and did not affect the rats' weight.
"We are satisfied with these results for two reasons. First, we were able to give rats a very high dose without mortality or side effects. In addition, there was no change in average body weight, weight gain, food consumption or feed efficiency in male and female rats attributable to Ramizol, "said Boulos.
"We believe that Ramizol may be the standard of treatment for the treatment of ICD and could become a star drug." Our research indicates that Ramizol is an extremely well-tolerated antibiotic in rats, with good microbiology and good properties antioxidants, "he concluded. "It also has high chemical stability and is scalable due to the low manufacturing cost, which could make it a viable treatment option."
[ad_2]
Source link
